The relationship between homocysteine and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention

Timor Omar; Yavuz Karabağ; Metin Öğün; İnanç Artaç; Muammer Karakayalı; Doğan İliş; Ayça Arslan; Cihan Dündar; İbrahim Rencüzoğulları

Makale detayları

The relationship between homocysteine and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention

Yazarlar:

Timor Omar | Yavuz Karabağ | Metin Öğün | İnanç Artaç | Muammer Karakayalı | Doğan İliş | Ayça Arslan | Cihan Dündar | İbrahim Rencüzoğulları

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Kardiyoloji

Dergi:

Journal of Health Sciences and Medicine Vol.7 Issue 2, pp.199-205

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001314056

pISSN:

2636-8579

Anahtar kelimeler:

Özet:

 Aims: The current study aimed to investigate the relationship between homocysteine and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention pPCI. Methods: Patients with ST-elevation myocardial infarctions STEMI who underwent pPCI in our center between May 01, 2022, and 20 August 2023 were included in this cross-sectional observational study. Patients were classified into two groups according to the occurrence of no-reflow during pPCI. Findings were compared between the two groups. Results: A total of 332 patients male, 75 82.8 with STEMI undergoing pPCI, were included. Among them, 35 10.5 patients developed no-reflow. Homocysteine level was significantly higher in the no-reflow group than the no-reflow- group median IQR, 19.02 16.11-22.23 vs. 12.45 10.99-14.93, p0.019. According to the multivariate analysis, homocysteine level, TIMI risk score, and postdilatation were independent predictors of no-reflow occurrence Odds Ratio 95 CI, 1.127 1.042-1.218, p0.003, 1.385 1.157-1.659, p0.001, and 2.396 1.092-5.257, p0.029, respectively. Considering the ROC curve analysis for homocysteine predicting no-reflow, the area under the curve AUC was 0.714 with an optimal cut-off value of 14.1 sensitivity of 71, specificity 62. Conclusion: Higher admission homocysteine levels were associated with no-reflow development in STEMI patients during pPCI. Higher levels of homocysteine may identify a subset of patients at a higher risk of no-reflow development during pPCI.

 Aims: The current study aimed to investigate the relationship between homocysteine and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention pPCI. Methods: Patients with ST-elevation myocardial infarctions STEMI who underwent pPCI in our center between May 01, 2022, and 20 August 2023 were included in this cross-sectional observational study. Patients were classified into two groups according to the occurrence of no-reflow during pPCI. Findings were compared between the two groups. Results: A total of 332 patients male, 75 82.8 with STEMI undergoing pPCI, were included. Among them, 35 10.5 patients developed no-reflow. Homocysteine level was significantly higher in the no-reflow group than the no-reflow- group median IQR, 19.02 16.11-22.23 vs. 12.45 10.99-14.93, p0.019. According to the multivariate analysis, homocysteine level, TIMI risk score, and postdilatation were independent predictors of no-reflow occurrence Odds Ratio 95 CI, 1.127 1.042-1.218, p0.003, 1.385 1.157-1.659, p0.001, and 2.396 1.092-5.257, p0.029, respectively. Considering the ROC curve analysis for homocysteine predicting no-reflow, the area under the curve AUC was 0.714 with an optimal cut-off value of 14.1 sensitivity of 71, specificity 62. Conclusion: Higher admission homocysteine levels were associated with no-reflow development in STEMI patients during pPCI. Higher levels of homocysteine may identify a subset of patients at a higher risk of no-reflow development during pPCI.

 Aims: The current study aimed to investigate the relationship between homocysteine and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention pPCI. Methods: Patients with ST-elevation myocardial infarctions STEMI who underwent pPCI in our center between May 01, 2022, and 20 August 2023 were included in this cross-sectional observational study. Patients were classified into two groups according to the occurrence of no-reflow during pPCI. Findings were compared between the two groups. Results: A total of 332 patients male, 75 82.8 with STEMI undergoing pPCI, were included. Among them, 35 10.5 patients developed no-reflow. Homocysteine level was significantly higher in the no-reflow group than the no-reflow- group median IQR, 19.02 16.11-22.23 vs. 12.45 10.99-14.93, p0.019. According to the multivariate analysis, homocysteine level, TIMI risk score, and postdilatation were independent predictors of no-reflow occurrence Odds Ratio 95 CI, 1.127 1.042-1.218, p0.003, 1.385 1.157-1.659, p0.001, and 2.396 1.092-5.257, p0.029, respectively. Considering the ROC curve analysis for homocysteine predicting no-reflow, the area under the curve AUC was 0.714 with an optimal cut-off value of 14.1 sensitivity of 71, specificity 62. Conclusion: Higher admission homocysteine levels were associated with no-reflow development in STEMI patients during pPCI. Higher levels of homocysteine may identify a subset of patients at a higher risk of no-reflow development during pPCI.

 Aims: The current study aimed to investigate the relationship between homocysteine and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention pPCI. Methods: Patients with ST-elevation myocardial infarctions STEMI who underwent pPCI in our center between May 01, 2022, and 20 August 2023 were included in this cross-sectional observational study. Patients were classified into two groups according to the occurrence of no-reflow during pPCI. Findings were compared between the two groups. Results: A total of 332 patients male, 75 82.8 with STEMI undergoing pPCI, were included. Among them, 35 10.5 patients developed no-reflow. Homocysteine level was significantly higher in the no-reflow group than the no-reflow- group median IQR, 19.02 16.11-22.23 vs. 12.45 10.99-14.93, p0.019. According to the multivariate analysis, homocysteine level, TIMI risk score, and postdilatation were independent predictors of no-reflow occurrence Odds Ratio 95 CI, 1.127 1.042-1.218, p0.003, 1.385 1.157-1.659, p0.001, and 2.396 1.092-5.257, p0.029, respectively. Considering the ROC curve analysis for homocysteine predicting no-reflow, the area under the curve AUC was 0.714 with an optimal cut-off value of 14.1 sensitivity of 71, specificity 62. Conclusion: Higher admission homocysteine levels were associated with no-reflow development in STEMI patients during pPCI. Higher levels of homocysteine may identify a subset of patients at a higher risk of no-reflow development during pPCI.

Makale detayları

The relationship between homocysteine and no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention

Yazarlar: Timor Omar | Yavuz Karabağ | Metin Öğün | İnanç Artaç | Muammer Karakayalı | Doğan İliş | Ayça Arslan | Cihan Dündar | İbrahim Rencüzoğulları

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Kardiyoloji

Dergi: Journal of Health Sciences and Medicine Vol.7 Issue 2, pp.199-205

Belge Tipi: Makale

Yayın Tarihi: 3/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001314056

pISSN: 2636-8579

no-reflow

homocysteine

STEMI

PCI

Sayı

Yazarlar:

Timor Omar | Yavuz Karabağ | Metin Öğün | İnanç Artaç | Muammer Karakayalı | Doğan İliş | Ayça Arslan | Cihan Dündar | İbrahim Rencüzoğulları

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Kardiyoloji

Dergi:

Journal of Health Sciences and Medicine Vol.7 Issue 2, pp.199-205

Belge Tipi:

Makale

Yayın Tarihi:

3/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001314056

pISSN:

2636-8579